Cargando…

Endocrinological features of a patient with 14q microdeletion and Dubowitz phenotype

BACKGROUND: Dubowitz syndrome (DS) is a complex and rare condition characterized by postnatal growth retardation, microcephaly, short stature, mild developmental delay, facial dysmorphism, skin eruption and bone marrow failure. Though approximately 200 cases have been described so far, no specific g...

Descripción completa

Detalles Bibliográficos
Autores principales: Amodeo, Maria Elisa, Inzaghi, Elena, Deodati, Annalisa, Cianfarani, Stefano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8172207/
https://www.ncbi.nlm.nih.gov/pubmed/33788412
http://dx.doi.org/10.1002/mgg3.1644
_version_ 1783702495656148992
author Amodeo, Maria Elisa
Inzaghi, Elena
Deodati, Annalisa
Cianfarani, Stefano
author_facet Amodeo, Maria Elisa
Inzaghi, Elena
Deodati, Annalisa
Cianfarani, Stefano
author_sort Amodeo, Maria Elisa
collection PubMed
description BACKGROUND: Dubowitz syndrome (DS) is a complex and rare condition characterized by postnatal growth retardation, microcephaly, short stature, mild developmental delay, facial dysmorphism, skin eruption and bone marrow failure. Though approximately 200 cases have been described so far, no specific genetic analysis, laboratory tests or radiological exams are available to confirm the diagnosis which is still based on clinical and facial features. Although short stature is a major feature of the syndrome, no endocrine alterations have been reported so far and scant data are available about the efficacy and safety of GH treatment in these patients. METHODS: A 13‐year‐old male patient was referred to our attention for short stature. Endocrinological evaluation including GH axis, adrenal and gonadal functions were assessed. aCGH was performed. RESULTS: 14q terminal microdeletion associated with Dubowitz phenotype was found. Endocrinological investigations revealed the presence of hypopituitarism which showed a satisfactory response to short‐term growth hormone therapy. The subject also started glucocorticoid replacement therapy. Disorders in pubertal progression and gonadal function were noted. CONCLUSIONS: Dubowitz syndrome (DS) includes different clinical findings variably occurring. Subjects with a Dubowitz phenotype should be carefully monitored for endocrinological anomalies. The prompt recognition of potential life‐threatening endocrinological condition for example adrenal insufficiency is mandatory in order to start an adequate and early treatment.
format Online
Article
Text
id pubmed-8172207
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-81722072021-06-11 Endocrinological features of a patient with 14q microdeletion and Dubowitz phenotype Amodeo, Maria Elisa Inzaghi, Elena Deodati, Annalisa Cianfarani, Stefano Mol Genet Genomic Med Clinical Reports BACKGROUND: Dubowitz syndrome (DS) is a complex and rare condition characterized by postnatal growth retardation, microcephaly, short stature, mild developmental delay, facial dysmorphism, skin eruption and bone marrow failure. Though approximately 200 cases have been described so far, no specific genetic analysis, laboratory tests or radiological exams are available to confirm the diagnosis which is still based on clinical and facial features. Although short stature is a major feature of the syndrome, no endocrine alterations have been reported so far and scant data are available about the efficacy and safety of GH treatment in these patients. METHODS: A 13‐year‐old male patient was referred to our attention for short stature. Endocrinological evaluation including GH axis, adrenal and gonadal functions were assessed. aCGH was performed. RESULTS: 14q terminal microdeletion associated with Dubowitz phenotype was found. Endocrinological investigations revealed the presence of hypopituitarism which showed a satisfactory response to short‐term growth hormone therapy. The subject also started glucocorticoid replacement therapy. Disorders in pubertal progression and gonadal function were noted. CONCLUSIONS: Dubowitz syndrome (DS) includes different clinical findings variably occurring. Subjects with a Dubowitz phenotype should be carefully monitored for endocrinological anomalies. The prompt recognition of potential life‐threatening endocrinological condition for example adrenal insufficiency is mandatory in order to start an adequate and early treatment. John Wiley and Sons Inc. 2021-03-31 /pmc/articles/PMC8172207/ /pubmed/33788412 http://dx.doi.org/10.1002/mgg3.1644 Text en © 2021 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals LLC. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Reports
Amodeo, Maria Elisa
Inzaghi, Elena
Deodati, Annalisa
Cianfarani, Stefano
Endocrinological features of a patient with 14q microdeletion and Dubowitz phenotype
title Endocrinological features of a patient with 14q microdeletion and Dubowitz phenotype
title_full Endocrinological features of a patient with 14q microdeletion and Dubowitz phenotype
title_fullStr Endocrinological features of a patient with 14q microdeletion and Dubowitz phenotype
title_full_unstemmed Endocrinological features of a patient with 14q microdeletion and Dubowitz phenotype
title_short Endocrinological features of a patient with 14q microdeletion and Dubowitz phenotype
title_sort endocrinological features of a patient with 14q microdeletion and dubowitz phenotype
topic Clinical Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8172207/
https://www.ncbi.nlm.nih.gov/pubmed/33788412
http://dx.doi.org/10.1002/mgg3.1644
work_keys_str_mv AT amodeomariaelisa endocrinologicalfeaturesofapatientwith14qmicrodeletionanddubowitzphenotype
AT inzaghielena endocrinologicalfeaturesofapatientwith14qmicrodeletionanddubowitzphenotype
AT deodatiannalisa endocrinologicalfeaturesofapatientwith14qmicrodeletionanddubowitzphenotype
AT cianfaranistefano endocrinologicalfeaturesofapatientwith14qmicrodeletionanddubowitzphenotype